Clinical trial · Interventional
Leucine-enriched Formulas in Patients With Tumor-induced Sarcopenia
Standard Hypercaloric, Hyperproteic vs Leucine-enriched Oral Supplements in Patients With Cancer-induced Sarcopenia
NCT05837741CI-TRIAL-00066286completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Currently there is a lack of evidence for recommending specific oral supplements (OS) for nutritional support in patients with cancer, including leucine-enriched supplements.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Leucine-enriched hypercaloric hyperproteic oral nutritional supplement | Dietary Supplement | — | UNRESOLVED |
| Standard hypercaloric hyperproteic oral nutritional supplement | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard hypercaloric, hyperproteic oral supplement
- description
- Patients will receive 2 supplements per day (Standard hypercaloric, hyperproteic oral supplement)
- interventionNames
- Dietary Supplement: Standard hypercaloric hyperproteic oral nutritional supplement
- type
- ACTIVE_COMPARATOR
- label
- Leucin-enriched hypercaloric, hyperproteic oral supplement
- description
- Patients will receive 2 supplements per day (Leucin-enriched hypercaloric, hyperproteic oral supplement)
- interventionNames
- Dietary Supplement: Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Primary outcomes (1)
- measure
- Muscle mass gain
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * patients of both sexes, age \> 18 y-old * cancer of different origin treated with systemic treatment chemo, radiotherapy or combination treatment t * weight loss \>5% during the previous three months or \>10% during the previous six months Exclusion Criteria: * end-stage kidney disease * life expectancy \< 2 weeks
References
Publications (0)
Data not yet available
No reference posted for this study.